Intelligence · Clinical Pipeline

Autoimmune & immunology · Phase III

Autoimmune & immunology programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs: 368

Quick answer

Autoimmune & immunology Phase III programs: NovaPharmaNews indexes 368 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

-, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, -

Novartis Pharmaceuticals

warm autoimmune haemolytic anaemia (wAIHA)

phase 3 small molecule active

1 trial
-, PARACETAMOL , CILAZAPRIL , Dapirolizumab pegol, EPINEPHRINE , DIPHENHYDRAMINE , -, -, -, -, -, -, -

Lacuna Pharma Pty Ltd

Systemic lupus erythematosus (SLE)

phase 3 small molecule active

1 trial
-, Rozanolixizumab

Lacuna Pharma Pty Ltd

Generalized Myasthenia Gravis

phase 3 small molecule active

1 trial
-, Rozanolixizumab

Lacuna Pharma Pty Ltd

Generalized Myasthenia Gravis

phase 3 small molecule active

1 trial
25 mg Ontamalimab

Takeda

Crohn's Disease

phase 3 small molecule completed

1 trial
608

Sunshine Guojian Pharmaceutical (Shanghai) Co.,

Axial Spondyloarthritis, Non-Radiographic

phase 3 small molecule active

1 trial
608 Q2W

Sunshine Guojian Pharmaceutical (Shanghai) Co.,

Plaque Psoriasis Patients

phase 3 small molecule active

1 trial
608 Q2W

Sunshine Guojian Pharmaceutical (Shanghai) Co.,

Psoriasis

phase 3 small molecule completed

1 trial
750 mg Imsidolimab

Vanda Pharmaceuticals Netherlands B.V.

Generalized Pustular Psoriasis

phase 3 small molecule completed

1 trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

Hoffmann-La Roche

NMDAR or LGI1 mediated autoimmune Encephalitis

phase 3 other active

1 trial
A clinical study is aimed at comparing the effectiveness of two types of cell therapy in treating anal fistulas associated with Crohn's disease.

COLLEGIUM PHARMACEUTICAL, INC

Anal or recto-cutaneous or recto-vaginal Crohn-related fistula

phase 3 other active

1 trial
ABBV-066 / Risankizumab, ABBV-066, Entyvio 300 mg powder for concentrate for solution for infusion

AbbVie Deutschland GmbH & Co. KG

Ulcerative Colitis

phase 3 small molecule active

1 trial
ABBV-066 / Risankizumab, Risankizumab, Matching Placebo for 90 mg solution for injection, ABBV-066, Matching placebo for 180 mg solution for injection

AbbVie Deutschland GmbH & Co. KG

Crohn's disease

phase 3 small molecule active

1 trial
AIN457 150 mg

Novartis Pharmaceuticals

Moderate to Severe Chronic Plaque-Type Psoriasis

phase 3 small molecule completed

1 trial
ALXN1720 Placebo Product, Gefurulimab

Alexion Europe SAS

Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

phase 3 small molecule active

1 trial
AMZ001 Diclofenac gel

Amzell

Osteoarthritis of Knee

phase 3 small molecule completed

1 trial
ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection

argenx

Generalized Myasthenia Gravis

phase 3 small molecule active

1 trial
ARQ-151 0.3% cream

Arcutis Biotherapeutics

Chronic Plaque Psoriasis

phase 3 small molecule completed

1 trial
AXS-02

Axsome Therapeutics

Osteoarthritis, Knee

phase 3 small molecule active

1 trial
Adalimumab

AbbVie

Juvenile Psoriatic Arthritis

phase 3 small molecule active

1 trial
Adalimumab

AbbVie

Psoriatic Arthritis

phase 3 small molecule completed

1 trial
Afimkibart

Hoffmann-La Roche

Moderately to Severely Active Crohns Disease

phase 3 small molecule active

1 trial
Alicaforsen

IONIS PHARMACEUTICALS INC

Crohn's Disease

phase 3 small molecule completed

2 trials
Amchafibrin

Lxo Ireland Designated Activity Company

Osteoarthritis, Knee

phase 3 small molecule completed

1 trial
Amifampridine Phosphate

CATALYST PHARMACEUTICALS, INC.

Myasthenia Gravis, Generalized

phase 3 small molecule completed

1 trial
Amifampridine Phosphate

CATALYST PHARMACEUTICALS, INC.

Myasthenia Gravis, MuSK

phase 3 small molecule terminated

1 trial
Anifrolumab

AstraZeneca

Cutaneous Lupus Erythematosus

phase 3 other active

1 trial
Anifrolumab

AstraZeneca

Active Systemic Lupus Erythematosus

phase 3 mab completed

3 trials
Anifrolumab

AstraZeneca AB

Moderate-to-severe Systemic Lupus Erythematosus (SLE)

phase 3 small molecule active

1 trial
Anifrolumab

AstraZeneca

Lupus Nephritis

phase 3 small molecule active

1 trial
Anifrolumab

AstraZeneca

Systemic Lupus Erythematosus

phase 3 mab active

1 trial
Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume

AstraZeneca AB

Cutaneous Lupus Erythematosus

phase 3 small molecule active

1 trial
Apitox, purified honeybee toxin, lyophilized in saline

Apimeds Pharmaceuticals US

Osteoarthritis of the Knee

phase 3 mab completed

1 trial
Apremilast 20mg

Amgen

Psoriatic Arthritis

phase 3 small molecule completed

1 trial
Apremilast, Apremilast, Apremilast

Amgen

Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

phase 3 small molecule active

1 trial
Apremilast, Apremilast, Apremilast, Apremilast placebo product is supplied to the clinic as 10, 20 and 30 mg tablets and 5 mg/mL oral solution. The placebo product is the same as the drug product formulation except there is no active apremilast., Apremilast

Amgen

Juvenile psoriatic arthritis

phase 3 small molecule active

1 trial
Asacol®

Tillotts Pharma AG

Active Ulcerative Colitis

phase 3 small molecule completed

1 trial
Atacicept

Vera Therapeutics

Lupus Nephritis (LN)

phase 3 small molecule terminated

1 trial
Azathioprine

The First People's Hospital of Lianyungang

Myasthenia Gravis

phase 3 small molecule completed

1 trial
B007

BRIGHT MINDS BIOSCIENCES INC.

Generalized Myasthenia Gravis

phase 3 small molecule active

1 trial
BARICITINIB, Baricitinib, BARICITINIB, BARICITINIB

Eli Lilly Co.

Juvenile Idiopathic Arthritis

phase 3 small molecule active

1 trial
BI 1015550, Placebo matching nerandomilast (BI 1015550)

Boehringer Ingelheim

Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

phase 3 small molecule active

1 trial
BI 695501

Boehringer Ingelheim

Arthritis, Rheumatoid

phase 3 small molecule completed

2 trials
BIIB059

Biogen

1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

phase 3 small molecule active

1 trial
BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

Biogen

Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

phase 3 small molecule active

1 trial
BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

Biogen

systemic lupus erythematosus

phase 3 small molecule active

1 trial
BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient

Biogen

systemic lupus erythematosus

phase 3 small molecule active

1 trial
BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.

Biogen

Systemic lupus erythematosus

phase 3 small molecule active

1 trial

Frequently asked questions

How many autoimmune & immunology Phase III programs exist?

368 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Quick answer

Top sponsors

-, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, -

-, PARACETAMOL , CILAZAPRIL , Dapirolizumab pegol, EPINEPHRINE , DIPHENHYDRAMINE , -, -, -, -, -, -, -

-, Rozanolixizumab

-, Rozanolixizumab

25 mg Ontamalimab

608

608 Q2W

608 Q2W

750 mg Imsidolimab

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

A clinical study is aimed at comparing the effectiveness of two types of cell therapy in treating anal fistulas associated with Crohn's disease.

ABBV-066 / Risankizumab, ABBV-066, Entyvio 300 mg powder for concentrate for solution for infusion

ABBV-066 / Risankizumab, Risankizumab, Matching Placebo for 90 mg solution for injection, ABBV-066, Matching placebo for 180 mg solution for injection

AIN457 150 mg

ALXN1720 Placebo Product, Gefurulimab

AMZ001 Diclofenac gel

ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion, Vyvgart 1 000 mg solution for injection

ARQ-151 0.3% cream

AXS-02

Adalimumab

Adalimumab

Afimkibart

Alicaforsen

Amchafibrin

Amifampridine Phosphate

Amifampridine Phosphate

Anifrolumab

Anifrolumab

Anifrolumab

Anifrolumab

Anifrolumab

Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume

Apitox, purified honeybee toxin, lyophilized in saline

Apremilast 20mg

Apremilast, Apremilast, Apremilast

Apremilast, Apremilast, Apremilast, Apremilast placebo product is supplied to the clinic as 10, 20 and 30 mg tablets and 5 mg/mL oral solution. The placebo product is the same as the drug product formulation except there is no active apremilast., Apremilast

Asacol®

Atacicept

Azathioprine

B007

BARICITINIB, Baricitinib, BARICITINIB, BARICITINIB

BI 1015550, Placebo matching nerandomilast (BI 1015550)

BI 695501

BIIB059

BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient

BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.

Frequently asked questions

Stay Ahead in Pharma